Purpose: The recent emergence of radioligand therapies for cancer treatment has increased
enthusiasm for developing new theranostic strategies coupling both imaging and cytotoxicity …

Background: CUB domain-containing protein 1 (CDCP1) is a cell surface receptor regulating
key signalling pathways in malignant cells. CDCP1 has been proposed as a molecular …

Rationale: An antibody-drug conjugate (ADC) is a targeted therapy consisting of a cytotoxic
payload that is linked to an antibody which targets a protein enriched on malignant cells …

CUB domain–containing protein 1 (CDCP1) is a membrane protein that is highly expressed
in several solid cancers. We reported previously that CDCP1 regulates anoikis resistance as …

The prognosis of pancreatic cancer is dismal due to the frequent metastasis and invasion to
surrounding organs. Numerous molecules are involved in the malignant behavior of …

In the last few years dysregulated expression of the cell surface glycoprotein CUB domain‐
containing protein 1 (CDCP1) has been associated with several cancers and this cell …

CUB-domain containing protein 1 (CDCP1) is a type I transmembrane glycoprotein that is
upregulated in malignancies of the breast, lung, colorectum, ovary, kidney, liver, pancreas …

Despite significant progress and notable successes in tumor therapy, malignant disease
remains an extremely difficult problem in today's health care setting. There is, however, an …

Abstract CUB-domain-containing-protein-1 (CDCP1) is an integral membrane protein whose
expression is up-regulated in various cancer types. Although high CDCP1 expression has …

Through a whole-cell panning approach, we previously identified a panel of antibodies that
bound to prostate cancer cell surface antigens. One such antigen, CUB domain-containing …